Steroid Hormone Powder Medroxyprogesterone Acetate
Product Name: Medroxyprogesterone 17-acetate
Synonyms: (6-alpha)-17-(acetyloxy)-6-methylpreg-4-ene-3,20-dione;17-(acetyloxy)-6-methyl-(6-alpha)-pregn-4-ene-20-dione;17-(acetyloxy)-6-methyl-20-dion(6alpha)-pregn-4-ene-;17-acetoxy-6-alpha-methylprogesterone;17-alpha-hydroxy-6-alpha-methylpregn-4-ene-3,20-dioneacetate;17-alpha-hydroxy-6-alpha-methyl-progesteronacetate;17-alpha-hydroxy-6-alpha-methylprogesteroneacetate;17-hydroxy-6-alpha-methylpregn-4-ene-3,20-dioneacetate
CAS: 71-58-9
MF: C24H34O4
MW: 386.52
EINECS: 200-757-9
What is Medroxyprogesterone Acetate
Medroxyprogesterone Acetate is a more potent derivative of its parent compound medroxyprogesterone (MP). Medroxyprogesterone is a synthetic variant of the steroid hormone progesterone(progestin). Progestins and estrogens are the two major classes of female hormones. While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is almost always being referred to is MPA and not MP.
Chemical Properties
Melting point 206-207 °C(lit.)
alpha D +61° (in chloroform)
refractive index 48 ° (C=1, Dioxane)
storage temp. Refrigerator
Water Solubility <0.1 g/100 mL at 23 ºC
Merck 13,5817
Stability:Stable, but weakly air and light sensitive. Incompatible with strong oxidizing agents.
Benefits:
Highly effective at preventing pregnancy.
Injected every 12 weeks. The only continuing action is to book subsequent follow-up injections every twelve weeks, and to monitor side effects to ensure that they do not require medical attention.
No estrogen. No increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction.
Minimal drug interactions (compared to other hormonal contraceptives).
Decreased risk of endometrial cancer. Depo-Provera reduces the risk of endometrial cancer by 80%.The reduced risk of endometrial cancer in Depo-Provera users is thought to be due to both the direct anti-proliferative effect of progestogen on the endometrium and the indirect reduction of estrogen levels by suppression of ovarian follicular development.
Decreased risk of iron deficiency anemia, pelvic inflammatory disease (PID), ectopic pregnancy, and uterine fibroids.
Decreased symptoms of endometriosis.
Decreased incidence of primary dysmenorrhea, ovulation pain, and functional ovarian cysts.
Decreased incidence of seizures in women with epilepsy. Additionally, unlike most other hormonal contraceptives, Depo-Provera's contraceptive effectiveness is not affected by enzyme-inducing antiepileptic drugs.
Decreased incidence and severity of sickle cell crises in women with sickle-cell disease.
Medical uses
1. Birth control
Estimates of first-year failure rates are about 0.3%.
2. Perfect use
Trussell's estimated perfect use first-year failure rate for medroxyprogesterone acetate by injection as the average of failure rates in seven clinical trials at 0.3%. It was considered perfect use because the clinical trials measured efficacy during actual use of medroxyprogesterone acetate defined as being no longer than 14 or 15 weeks after an injection (i.e., no more than 1 or 2 weeks late for a next injection).
Specification:
TEST ITEMS | SPECIFICATION | RESULTS |
Description | : White Crystalline Powder | White Powder |
Identification | : Positive | Positive |
Assay(by HPLC) | : 98.0~102.0% | 98.64% |
Absorbance(E1cm) | : 465~495 | 482.5 |
Melting Point | : 191~195 | 193.5~195.0 |
Loss On Drying | : 0.5%max | 0.19% |
Specific Rotation | : +288~ +298 | +290.2 |
Residue On Ignition | : 0.1%max | 0.03% |
Related Substances | : Total:1.5%max | <1.3% |
Single:0.5%max | <0.4% | |
Residue Solvents | : 0.2%max | 0.10% |
Heavy Metals | : 20PPm max | <10PPm |
